(Total Views: 284)
Posted On: 03/25/2019 7:53:59 PM
Post# of 36509
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
“The 630,871 increase in research and development expenses in the quarter ended January 31, 2019 versus the comparative previous fiscal quarter is primarily due Antigen’s increase of expenses.”
Good $NGIO.
Good $NGIO.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)